Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

49.58 +0.70 (+1.43%)
Streaming Delayed Price Updated: 12:31 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Why BridgeBio Pharma Was a Healthy Stock Today
One of the best-performing biotechs on the stock market this year gets a bullish nod from a researcher. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
 
Via Benzinga
The Latest Analyst Ratings for BridgeBio Pharma
 
Via Benzinga
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 8/18
Via Investor Brand Network
4 Analysts Have This to Say About BridgeBio Pharma
 
Via Benzinga
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
From National Resilience, Inc.
Via Business Wire
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. 
Via InvestorPlace
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
What's Going On With BridgeBio Pharma Stock Today?
BridgeBio Pharma Inc (NASDAQ: BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the  
Via Benzinga
Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better.
The companies are expected to compete in a genetic heart disease beginning in late 2024. 
Via Investor's Business Daily
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
Its potential upcoming drug launch might not be enough. 
Via The Motley Fool
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
7 A-Rated Stocks for Your August Buy List
August is shaping up to be a great month for the stock market. Now you just need to make sure you own these A-rated stocks. 
Via InvestorPlace
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next. 
Via The Motley Fool
Why Shares of BridgeBio Pharma Skyrocketed This Week
The biotech company saw strong results in a phase 3 trial. 
Via The Motley Fool
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.